- Home
- CPRI vs RLAY Comparison
CPRI vs RLAY Comparison
Compare CPRI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRI | RLAY |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | 192 |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.8B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPRI | RLAY |
|---|---|---|
| Price | $19.14 | $18.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $26.62 | $19.50 |
| AVG Volume (30 Days) | ★ 3.7M | 3.6M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.40 | 31.78 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,474,000,000.00 | $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.81 | $324.03 |
| P/E Ratio | $16.80 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $16.72 | $3.03 |
| 52 Week High | $28.27 | $17.70 |
Technical Indicators
Market Signals| Indicator | CPRI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 74.26 |
| Support Level | $16.82 | $6.67 |
| Resistance Level | $22.25 | N/A |
| Average True Range (ATR) | 0.83 | 0.96 |
| MACD | -0.09 | 0.36 |
| Stochastic Oscillator | 13.90 | 87.98 |
Price Performance
Historical ComparisonAbout CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.